All In Biotech

Drug Trial Radar · NCT07597902

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction (SHIELD)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
PridCor Therapeutics
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).

Conditions

  • Post-acute Sequelae of COVID-19
  • Long COVID

Interventions

  • ValacyclovirDrug

    one to two 750mg capsules taken orally in the morning and evening

  • CelecoxibDrug

    200mg capsules taken orally in the morning and evening

  • PaxlovidDrug

    one (100mg ritonavir tablet and two 150mg nirmatrelvir tablets) taken orally in the morning and evening

  • PlaceboDrug

    matching placebo capsules and tablets taken orally in the morning and evening

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EQ-5D-5L Visual Analogue Scale (VAS)Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.